Welcome to our dedicated page for Senseonics Holdings news (Ticker: SENS), a resource for investors and traders seeking the latest updates and insights on Senseonics Holdings stock.
Senseonics Holdings, Inc. reports developments tied to its long-term, implantable continuous glucose monitoring systems for people with diabetes. The company designs, develops, manufactures and commercializes the Eversense CGM platform, including Eversense 365 and Eversense E3, which use an under-the-skin sensor, a wearable smart transmitter and a mobile app for glucose data.
Recurring news for SENS covers financial results, U.S. and European commercialization, CE Mark and product-launch activity, automated insulin delivery integrations, and pipeline work on Gemini and Freedom systems. Company updates also include capital actions such as common stock and pre-funded warrant offerings, loan-facility amendments, and funding for Eversense 365 commercialization and product development.
Senseonics (NASDAQ: SENS) will release first quarter 2026 financial results after market close on Thursday, May 7, 2026. Management will host a conference call and concurrent webcast at 4:30 p.m. Eastern Time the same day.
The webcast link will be available via the company website under Investor Relations > Events & Publications and will be archived. Dial-in numbers: 1-800-225-9448 (US/Canada) or 1-203-518-9708 (International); passcode SENSQ1. Callers are asked to dial in approximately ten to five minutes before the start time.
Senseonics (NASDAQ: SENS) priced an underwritten public offering to raise gross proceeds of $80.0 million by offering 8,000,000 common shares at $5.00 per share and 8,000,000 pre-funded warrants at $4.999 each. The underwriters have a 30-day option to buy up to 2,400,000 additional shares. The offering is expected to close on May 4, 2026, subject to customary closing conditions. Net proceeds are intended to fund the Eversense 365 launch, pipeline development, working capital, and general corporate purposes.
Senseonics (NASDAQ: SENS) announced commencement of an $80 million underwritten public offering of common stock and pre-funded warrants, with an underwriter option to purchase up to an additional 15% of the shares. The pre-funded warrants will not be exchange-listed.
TD Cowen and Barclays are joint book-running managers; Mizuho and Lake Street are bookrunners. The offering is subject to market and other conditions under a Form S-3 shelf (File No. 333-289306). Net proceeds are intended to fund the launch of Eversense 365, pipeline development, working capital, and general corporate purposes.
Senseonics (NASDAQ: SENS) announced the European launch of Eversense 365, the world’s first one‑year implantable CGM, now available in Sweden with phased rollouts in Germany, Spain and Italy during the coming weeks. Eversense 365 doubles sensor lifespan from six months to 12 months, reduces calibrations from daily to weekly, and follows CE Mark approval in January and prior U.S. FDA approval in September 2024.
The company also highlighted real‑world evidence presented at ATTD showing sustained one‑year performance and an announced U.S. integration with Sequel Med Tech’s twiist Automated Insulin Delivery system.
Senseonics (NASDAQ:SENS) presented real-world data at ATTD (March 11-14, 2026) showing sustained performance of Eversense 365 across one year in 5,059 US sensors. Key metrics: mean GMI 7.14%, mean Time in Range 66%, transmitter wear 93.8%, and >75% meeting hypoglycemia targets.
Age subgroup gains included >65s with GMI 6.99%, TIR >70% and >95% wear; early AID combo data (n≈120) showed GMI 6.79% and TIR 77%.
Senseonics (NASDAQ: SENS) reported Q4 2025 revenue of $14.3M (up ~72% YoY) and full year 2025 revenue of $35.3M (up ~57% YoY). The company received CE Mark for Eversense 365, launched U.S. AID integration with twiist, secured an IDE for the Gemini pivotal trial and began enrollment.
Cash and investments stood at $94.3M with $35.3M debt. Senseonics expects 2026 revenue of $58–$62M and ~50% gross margin, reflecting commercialization transition and DTC marketing investments.
Senseonics (NASDAQ: SENS) and Sequel Med Tech announced full U.S. availability of the twiist Automated Insulin Delivery system integrated with the Eversense 365 continuous glucose monitor on Feb 19, 2026. twiist is the first AID compatible with a year‑long CGM, pairing twiist precision with Eversense 365's 365 days of continuous readings to reduce sensor changes and re‑pairing while maintaining high CGM accuracy.
The combination is in real‑world care settings and offers people with type 1 diabetes an alternative to shorter‑duration sensors.
Senseonics (NASDAQ: SENS) received CE Mark approval for the Eversense 365 continuous glucose monitor, clearing commercialization across the EU and enabling planned launches in Germany, Italy, Spain, and Sweden in the coming months. The device is the first one-year implantable CGM, following FDA clearance and U.S. launch in 2024. The company says the approval expands its reachable EU patient population by over 30 million and positions Eversense 365 for integration with automated insulin delivery systems.
Senseonics (NASDAQ: SENS) announced management will participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 11, 2026 in Snowbird, Utah.
Investors seeking a meeting are advised to contact their BTIG representatives to request a meeting with Senseonics management.
Senseonics (NASDAQ: SENS) reported preliminary unaudited Q4 2025 revenue of ~$14.2M (+71% YoY) and preliminary full‑year 2025 revenue of ~$35.2M (+~57% YoY), the largest quarterly and annual revenue in company history. The company expects to report audited results after market close on March 2, 2026 and held cash of approximately $94.3M as of December 31, 2025. Senseonics introduced 2026 revenue guidance of $58–$62M (≈65%–76% growth) and forecasted ~50% gross margin. Company highlights include 103% U.S. new patient growth in Q4, FDA IDE approval and enrollment for the Gemini pivotal trial, and the commercial transition of Eversense 365 from Ascensia effective January 1, 2026.